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SUMMARY
Toxoplasmosis is an important cause of congenital infection. The present study was performed to evaluate the usefulness of 
recombinant (r) GRA-7 cloned from nucleotides (n) 39-711 in discriminating between acute and chronic toxoplasmosis. First, 
commercial IgM, IgG and IgG avidity ELISAs were used to determine the serological profile of the sera. Serum samples were from 
20 symptomatic patients with acute infection (low IgG avidity, IgM positive), 10 with chronic infection (high IgG avidity, IgM 
negative) and 10 with indeterminate IgG avidity (IgM positive) which were tested for IgG avidity status with an in-house developed 
IgG avidity Western blot using the rGRA-7 recombinant antigen. All 20 sera from cases of probable acute infection showed bands 
which either faded out completely or reduced significantly in intensity after treatment with 8 M urea, whereas the band intensities 
of the 10 serum samples from chronic cases remained the same. Of the 10 sera with indeterminate IgG avidity status, after treatment 
with 8 M urea the band intensities with six sera remained the same, two sera had completely faded bands and another two sera had 
significantly reduced band intensities. Discrimination between acute and chronic toxoplasmosis was successfully performed by the 
in-house IgG avidity Western blot.
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INTRODUCTION
Toxoplasmosis is an infection caused by the obligate intracellular 
parasite Toxoplasma gondii which infects a large variety of domestic 
and wild mammals, including humans11. T. gondii infection in humans 
is generally asymptomatic and induces a self-limiting disease. However, 
in pregnant women, immunosuppressed patients and those with ocular 
involvement, the clinical outcome can be very serious. An acute infection 
with T. gondii acquired during the first trimester of pregnancy can result 
in intrauterine transmission to the unborn fetus, severe fetal and neonatal 
complications including mental retardation, retinochoroiditis, blindness, 
and death13,17. Therefore it is crucial to identify the gestational age of 
primary infection for the clinical management of pregnant women, 
since the severity of fetal toxoplasmosis decreases and maternal to 
fetal transmission rate increases as gestational age progresses7,26. The 
diagnostic challenge is presented when Toxoplasma-specific IgG and IgM 
antibodies are found in first sample after conception, since estimation of 
the time of infection is crucial to determine whether the fetus is at risk8.
Routine diagnosis of T. gondii infection relies mainly on serological 
detection of specific anti-Toxoplasma IgG, IgM and IgA antibodies24, but 
the results of these assays are not able to estimate the time of infection 
with accuracy6,10. An assay measuring the antigen-binding avidity of IgG 
antibodies against T. gondii has proven to be a highly useful procedure 
for serological diagnosis of Toxoplasma infections3,4,16. This is especially 
apparent in situations where timing and differentiation of primary and 
secondary infections is crucial17. Using IgG avidity assay, acute infection 
can be diagnosed using a single serum specimen, and further primary 
infection can be distinguished from secondary (recurrent or reactivated) 
infections. In the past many different methods have been to measure IgG 
avidity, however most of these are laborious and unsuitable for diagnostic 
laboratories14. Also in nearly all these kits various preparations of lysed 
whole-cell T. gondii antigens are utilized, which might be contaminated 
by non-parasitic materials. One way to overcome this problem is to 
use recombinant antigens, which can improve the standardization and 
performance of the IgG avidity assay in terms of quality and consistency.
As the avidity test is dependent on the presence of specific IgG, it is 
very important to use an antigen which elicits humoral response at the 
acute stage of infection. In a previous study, we have identified rGRA-
7 (P29) sequence of n39-711 as a molecule that reacted strongly with 
IgG antibody in acute sera samples, and thus holds good potential to be 
used in discriminating between probable acute and chronic cases of T. 
gondii infection12. Therefore in the present study, we developed an in-
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house modified immunoblot technique (IgG avidity Western blot) using 
rGRA-7 recombinant antigen (n39-711) to discriminate between high and 
low IgG antibody avidity in sera samples of T. gondii-infected patients.
MATERIALS AND METHODS
The study was performed during the period from June 2010 to 
February 2011 at the Institute for Research in Molecular Medicine, 
Penang, Malaysia.
Serum samples: These comprised samples from pregnant women or 
patients suspected of toxoplasmosis and previously tested for the presence 
of IgM and/or IgG antibodies to T. gondii. The samples were previously 
collected with prior informed consents of the individuals. Approval for 
use of the banked samples was obtained from Universiti Sains Malaysia 
Human Research Ethics Committee, which conforms to the principles 
of the Helsinki Declaration of 1975, as revised in 1983. A total of 40 
human serum samples were analyzed and divided into three groups based 
on serological profiles derived after performing commercially available 
immunoassays, namely PlateliaTM Toxo IgG Indirect EIA, PlateliaTM Toxo 
IgM, and PlateliaTM IgG avidity-ELISA (Bio-Rad, France). The cut-off 
OD for low avidity result in the Platelia IgG avidity-ELISA was 0.400. 
One group of sera (Group 1) consisted of 20 human serum samples 
from patients with probable acute phase toxoplasmosis. The patients had 
clinical symptoms consistent with acute toxoplasmosis and demonstrated 
the following serological profile : optical density (OD) of IgM-ELISA > 
1.000, IgG-ELISA positive, Avidity Index (AI) of IgG-avidity ELISA < 
0.250. The second group of sera (Group II) consisted of 10 human serum 
samples from individuals with serological profile indicative of chronic 
infection i.e. positive for IgM-ELISA and IgG-ELISA, AI of IgG-avidity 
ELISA > 0.500. The third group of sera (Group III) consisted of 10 
human serum samples from individuals who were suspected of having 
toxoplasmosis, and the serological profile was as follows i.e. positive 
for IgM-ELISA and IgG-ELISA, AI of IgG-avidity ELISA was between 
0.400 to 0.500 which suggested intermediate IgG avidity. All human 
serum samples were stored at -20 °C until tested.
Toxoplasma recombinant antigen: rGRA-7 was previously cloned 
from nucleotides 39-711 (amino acids 14-236), GenBank accession 
No HM016952. The antigen was expressed efficiently in bacterial cells 
as insoluble protein and was purified by affinity chromatography14. 
Briefly, recombinant Escherichia coli was induced with isopropyl-β-d-
thiogalactopyranoside (IPTG), centrifuged, and suspended in lysis buffer 
(50 mM sodium dihydrogen phosphate, 500 mM sodium chloride, 10 
mM imidazole and 0.1% Triton-X 100) containing cocktail of protease 
inhibitor (Roche, Germany, 14.8 µg/mL) and lysozyme (Amresco, 
Solon, Ohio, 0.5 mg/mL). The cells were lysed using French Press 40K 
(Thermo Spectronic, USA) followed by centrifugation at 12,000 g, 4 
ºC for 30 minutes to separate the supernatant and pellet. Subsequently 
the pellet was dissolved in denaturing lysis/binding buffer (7M Urea, 
100mM NaH2PO4, 10mM Tris-HCl, pH 8.0) and centrifuged to pellet any 
insoluble debris and the soluble fraction was used for further purification 
steps. After DNase I treatment, the protein fraction was incubated with 
Ni-NTA resin. After loading, the column was washed with denaturing 
washing buffer (8M urea, 100 mM NaH2PO4, 10 mM Tris-HCl, pH 
6.3) and eluted with denaturing buffer (pH 5.9) and elution buffer (pH 
4.5). Purified fractions were pooled and elution buffer was exchanged 
with storage buffer 50 mM Tris-HCl, 150 mM NaCl, 5% Glycerol, pH 
8.0) using Vivaspin column, cut-off 3kDa (Sartorius, Germany) and the 
concentrated protein was stored at -80 ºC.
IgG Avidity ELISA: This test was carried out using Platelia™ TOXO 
IgG AVIDITY kit (Bio-Rad, France) in conjunction with Platelia™ 
TOXO IgG assay kit. This test has to be used only on samples that 
demonstrate an anti-T. gondii IgG concentration higher or equal to 9 IU/
mL with Platelia™ TOXO IgG. Avidity controls and patient sera with a 
concentration of anti-T. gondii IgG between 9 and 80 IU/mL were diluted 
to 1/101. Sera from patients with a concentration of anti-T. gondii IgG 
equal or higher than 80 IU/mL were diluted to 1/808. Each control and 
patient serum sample was treated with control solution and dissociating 
solution for 15 minutes at room temperature. After incubation, both 
solutions and dissociated IgG antibodies were removed by through 
washing. Then 200 µL conjugate (anti-human IgG conjugated with 
horseradish peroxidase) was added to the microplate wells and incubated 
at 37 °C for further one hour. The unbound conjugate was removed by 
washing at the end of the incubation and 200 µL of substrate was added 
in each well. After incubation for 30 minutes at room temperature the 
enzymatic reaction was stopped by adding 100 µL of stop solution. The 
optical density readings were obtained with a spectrophotometer set at 
450/620 nm, and are proportional to the amount of IgG antibodies to T. 
gondii. An Avidity index (AI) of ≥ 0.500 was considered an indicator 
of anti-Toxoplasma IgG with high avidity, an AI of < 0.400 indicated 
low avidity, and an AI between 0.400 to 0.500 suggested intermediate/
borderline avidity.
IgG Avidity Western blot: 1 µg of rGRA-7 was loaded per well 
on 10% SDS-PAGE and the protein was transferred onto 0.45 µm 
nitrocellulose membrane (Bio-Rad, France). The membrane was then 
blocked with 5% fat-free milk in PBS for one h and then washed thrice 
with wash buffer (PBS-T). The membrane was cut in the form of strips 
and was incubated in duplicate with single serum samples (diluted 1:800 
in PBS) for one hour at room temperature followed by one hour at 37 °C 
with gentle rocking. After incubation, one strip of the duplicate serum 
was incubated with PBS-T and other strip was washed with 8M Urea in 
PBS-T for 5, 10 and 15 minutes. Finally, all the nitrocellulose strips (with 
and without urea treatment) of each serum sample were subjected to three 
washing cycles with PBS-T for 5, 10 and 15 minutes. The washed strips 
were incubated with secondary antibody peroxidase conjugated mouse 
anti-human IgG (Invitrogen) diluted at 1:10,000 for one hour at room 
temperature. Following being washed three times with PBS-T, the strips 
were developed using chemiluminescence blotting substrate (Thermo 
Scientific, USA) and Kodak films (Kodak, USA).
RESULTS
Fig. 1 shows the result of the Western blot using T. gondii rGRA7 
probed with human serum samples from Groups 1 and II, when subjected 
to a washing solution with or without 8 M urea. The antigenic bands with 
all 20 sera from Group I (acute infection) either faded out completely (n 
= 11) or the intensity reduced significantly (n = 9) when washed with 8 
M urea, as compared with washing without urea (Table 1A). On the other 
hand antigenic bands with all 10 sera from Group II (chronic infection) 
did not change in intensity with or without treatment with 8 M urea (Fig. 
1, Table 1B). Meanwhile, with 10 sera from Group III, when treated with 
8M urea two of the sera showed band intensities which completely faded, 
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two sera had significantly reduced band intensities and six sera showed 
band intensities which remained the same (Table 1C).
DISCUSSION
The measurement of IgG avidity for serodiagnosis of Toxoplasma 
infection has been shown to be a very useful confirmatory procedure for 
discriminating between recently acquired and distant infections3,4,7,20. 
Accurate diagnosis is particularly important for pregnant women for 
timely therapeutic decisions4. Since the presence of anti-Toxoplasma IgG 
or IgM antibodies is not a very reliable indicator of infection acuteness, 
pregnant mothers presenting with these antibodies in their first sample 
constitute the greatest challenge for accurate diagnosis. The avidity 
of specific IgG antibodies is usually low in the beginning of infection 
and increases with time by antigen-driven B cell selection. A high IgG 
avidity index within the first trimester of pregnancy can usually exclude 
an infection acquired during gestation25. However it has been reported 
than in treated individuals, the IgG avidity maturation may be delayed15. 
In a study of 146 Japanese who were positive for T. gondii IgG antibody 
and either positive or equivocal for specific IgM, the investigations 
showed that testing the IgG avidity of the maternal blood combined with 
multiplex nested PCR of the amniotic fluid is very useful in diagnosing 
congenital toxoplasmosis27.
There are numerous test systems commercially available, and most 
are based on whole-cell T. gondii antigen. Avidity assays based on this 
antigen were reported to detect low or borderline (intermediate) avidity 
antibodies in many individuals with chronically infected individuals, 
whereas recombinant antigens produced more mature avidity indices 
in chronically-infected individuals, and can therefore better distinguish 
between acute and chronic infections18,21,23. 
Table 1
Presence of band in IgG avidity Western blot using rGRA7 (n 39-711) with low 
(A), high (B) and intermediate (C) IgG avidity sera and two kinds of wash buffer 
(A) IgG avidity Western blot with low IgG avidity sera
No. Serum code Avidity index PBST wash 8M Urea wash
1. Tg217 0.1495 + faint +
2. Tg212 0.2096 + -
3. Tg84 0.1820 + faint+
4. Tg98 0.2130 + faint +
5. Tg61 0.1807 + -
6. Tg60 0.376 + -
7. Tg62 0.2445 + faint +
8. Tg64 0.1700 + faint +
9. Tg30 0.261 + -
10. Tg66 0.229 + -
11. Tg83 0.323 + faint+
12. Tg59 0.2701 + -
13. Tg58 0.250 + -
14. Tg21 0.248 + -
15. Tg219 0.237 + faint+
16. Tg221 0.217 + faint+
17. Tg 254 0.258 + -
18. Tg225 0.268 + -
19. Tg 257 0.259 + -
20. Tg55 0.223 + faint+
(B) IgG avidity Western blot with high IgG avidity sera
No. Serum code Avidity index PBST wash 8M Urea wash
1. Tg50 1.032 + +
2. Tg54 0.909 + +
3. Tg102 0.778 + +
4. Tg105 0.640 + +
5. Tg106 0.605 + +
6. Tg111 0.758 + +
7. Tg116 0.795 + +
8. Tg215 0.764 + +
9. Tg 265 0.888 + +
10. Tg80 0.516 + +
(C) IgG avidity Western blot with intermediate IgG avidity sera
No. Serum code Avidity index PBST wash 8M Urea wash
1. Tg 101 0.419 + faint +
2. Tg 103 0.415 + -
3. Tg 104 0.491 + +
4. Tg 114 0.488 + +
5. Tg 119 0.412 + -
6. Tg 166 0.438 + +
7. Tg 177 0.423 + +
8. Tg 239 0.403 + faint +
9. Tg 240 0.478 + +
10. Tg 241 0.409 + +
+: band present; faint +: faint band present; - : band absent.
Fig. 1 - T.gondii rGRA-7 (n39-711) antigen recognized by specific IgG in sera of acute and 
chronic phase of infection. M = Marker, 1 = acute phase sera without urea treatment, 2 = 
same sera as 1 but treated with 8M urea; 3, 4 = chronic phase sera without and with 8M urea 
treatment respectively.
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The usefulness of single antigen based avidity assays has 
previously been reported by various investigators. MORCOLINO et 
al.18, investigated recognition of p16, p32, p38 by human serum in 
IgG immunoblotting avidity assay. They identified p38 band as a good 
antigenic marker for detecting low avidity IgG in acute toxoplasmosis, 
whereby there was significant decrease of their frequencies (from 80% 
to 0%) after treatment with urea solution. ELYASI et al.5, evaluated the 
usefulness of avidity ELISA based on recombinant GRA-6 antigen for 
distinguishing between acute and chronic Toxoplasma infection, and 
they showed better clinical usefulness and performance of GRA6 avidity 
assay than the commercially available Euroimmune avidity ELISA for 
exclusion of recent infection of less than four months.
In an effort to improve discrimination between acute and chronic 
infections, we have developed a protein-denaturing assay for determining 
IgG avidity against rGRA-7 recombinant protein (14-236aa, n39-711). 
This is an extension of our previous study in which we have reported 
the diagnostic potential of this molecule for diagnosis of acute infection 
using IgG assay. When compared to rSAG1, the rGRA7 was able to 
better discriminate between acute and chronic toxoplasmosis, and 
showed higher specificity12. In the present report, we further evaluated the 
potential of rGRA-7 recombinant protein (14-236aa, n39-711) in an IgG 
avidity assay using an in-house Western blot technique which involves 
the dissociation of the antigen-antibody interaction with urea-containing 
washing solution. In a preliminary study (not described elsewhere in this 
report), washing solutions containing 6M and 8M were compared, the 
latter was found to show greater reduction in band intensity with low 
IgG avidity sera, and no difference in intensity with high IgG avidity 
chronic sera (data not shown). This observation differed from the report 
by MARCOLINO et al.18, which showed no difference in IgG avidity 
between the treatments with 6 and 8 M urea solutions with samples from 
acute and chronic infections. 
GRA7 is found in the parasitophorous vacuole and the cytoplasm of 
the tachyzoite infected host cell. This explains why IgG antibody response 
against GRA7 is potentially higher in early infection9 and thus could 
be a good candidate to be used for diagnosis of acute toxoplasmosis. 
BEGHETTO et al.2 used ELISA avidity with GRA7 cloned from 
nucleotides 72-309 (24-103aa) and showed 36.5% mean avidity in serum 
samples collected after two months of infection. Meanwhile PFREPPER 
et al.21 showed that at the beginning of IgG response, antibody to GRA7 
(79-789 (1-236aa) and/or GRA8 were exclusively present in human 
sera, while those to MAG1 and SAG1 were not observed. In time course 
studies IgG antibody to GRA7 and GRA8 matured significantly earlier 
than SAG1 and MAG1. These recombinant antigens are being used 
in a commercial immunoblot avidity kit (recomLine, MIKROGEN, 
Germany).
The GRA7 protein has also been reported by others to react more with 
acute sera as compared to chronic sera1,19. PIETKIEWICZ et al.23 used 
GRA7 cloned from nucleotides 56-708(16-236aa) in combination with 
GRA1 and SAG1 recombinant proteins to differentiate between recent 
and late infection. The GRA7 segment used by PIETKIEWICZ et al.23 
was similar, but not exactly the same, to that used in the present study. 
A cocktail of three recombinant proteins (rGRA1, rSAG1, rGRA7) was 
used by PIETKIEWICZ et al.23, thus the IgG avidity results using rGRA7 
alone are not known. Furthermore, our previous results on rSAG1(used 
as part of the above antigen cocktail) differed from the results of another 
study by the same research team22. Our data showed that it was positive 
with 20% (4/20) of healthy seronegative individuals, thus not suitable 
for use in Toxoplasma diagnosis12, while PIETKIEWICZ et al.22 showed 
that it was not reactive (0/19) with this group of individuals. The different 
Toxoplasma immunoassays used to determine the serological status of 
the individuals may explain the difference in results.
In this study, the usefulness of rGRA-7 cloned from nucleotides 39-
711 (14-236aa) in an IgG avidity Western blot assay was compared with 
results of commercially available Platelia IgG Avidity ELISA (BioRad, 
USA). With the sera of Groups I and II there was 100% agreement of 
the avidity status between our in-house IgG avidity Western blot with the 
commercial ELISA kit. In addition, with Group III sera which showed 
intermediate results using the commercial kit, the IgG avidity Western 
blot was able to differentiate them into low and high IgG avidity groups. 
Thus in this study, the IgG avidity Western blot using rGRA7 (14-236aa) 
enabled categorization of all 40 serum samples into either low or high 
IgG avidity, without any indeterminate results. Nevertheless it would 
be necessary to test a much larger number of serum samples in order 
to confirm that the assay will solve or significantly reduce the problem 
of borderline results. A side by side comparison of the various reported 
cloned segments of rGRA7 using the same sera panel would be very 
useful in ascertaining the best gene segment for use in IgG avidity assay. 
In addition, development of an ELISA format of the IgG avidity assay 
based on rGRA7 (n39-711) would be useful in providing quantitative 
results that can facilitate inter-laboratory result comparisons. The 
development of a rapid lateral flow format of the test would be welcomed 
for use in settings lacking in facilities and trained personnel
In conclusion, this study showed the potential of discrimination 
between acute and chronic toxoplasmosis by an IgG avidity Western blot 
assay using GRA7 recombinant antigen cloned from the gene segment 
comprising nucleotides 39-711. 
RESUMO
Avidez do IgG pelo Western Blot usando o r GRA-7 do 
Toxoplasma gondii clonado de nucleotídeos 39-711 para 
sorodiagnóstico de toxoplasmose aguda
Toxoplasmose é uma causa importante de infecção congênita. O 
presente estudo foi feito para avaliar o uso do recombinante (r) GRA-7 
clonado de nucleotídeos (n) 30-711 para discriminar entre toxoplasmose 
aguda e crônica. Inicialmente IgM, IgG e ELISA avidez IgG comerciais 
foram usados para determinar o perfil sorológico do soro. Amostras de 
soro de 20 pacientes sintomáticos com infecção aguda (IgG avidez baixa, 
IgM positivo), 10 com infecção crônica (alta avidez IgG, IgM negativo) e 
10 com avidez IgG indeterminada (IgM positivo) que foram testados para 
o status de avidez IgG com um doméstico Western Blot desenvolvendo 
avidez IgG usando o rGRA-7 antígeno recombinante. Todos os 20 soros 
de provável infecção aguda mostraram bandas que ou se apagaram 
completamente ou tiveram a sua intensidade significantemente reduzida 
após tratamento com uréia 8 M, enquanto as intensidades das bandas 
das 10 amostras de soros de casos crônicos permaneceram iguais. Dos 
10 soros com status indeterminado de avidez de IgG, após tratamento 
com uréia 8 M a intensidade das bandas em seis soros permaneceram 
iguais, dois soros tiveram bandas apagadas completamente e dois outros 
tiveram significante redução da intensidade das bandas. Discriminação 
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entre toxoplasmose aguda e crônica foi feita com sucesso através do IgG 
avidez Western blot doméstico.
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